https://news.longevitytrader.com/ 2026-04-28 https://news.longevitytrader.com/authors 2026-04-30 https://news.longevitytrader.com/p/the-1000x-sentinel-4-overlooked-biotech-companies-with-asymmetric-upside 2026-04-30 Longevity Trader en 2026-04-30T17:10:23Z The 1000x Sentinel: 4 Overlooked Biotech Companies With Asymmetric Upside https://news.longevitytrader.com/p/major-breakthroughs-in-regenerative-medicine-favor-these-overlooked-companies 2026-04-30 Longevity Trader en 2026-04-30T16:59:51Z Major Breakthroughs in Regenerative Medicine Favor These Overlooked Companies https://news.longevitytrader.com/p/the-100b-drug-creating-a-new-market-no-one-is-pricing-in 2026-04-30 Longevity Trader en 2026-04-30T16:50:04Z The $100B Drug Creating a New Market No One Is Pricing In https://news.longevitytrader.com/p/the-aesthetics-boom-and-why-temporary-fixes-won-t-be-enough 2026-04-30 Longevity Trader en 2026-04-30T16:39:23Z The Aesthetics Boom—and Why Temporary Fixes Won’t Be Enough https://news.longevitytrader.com/p/the-hidden-layer-of-biotech-that-could-produce-the-biggest-winners 2026-04-30 Longevity Trader en 2026-04-30T16:29:39Z The Hidden Layer of Biotech That Could Produce the Biggest Winners https://news.longevitytrader.com/p/this-regenerative-medicine-company-looks-ipo-ready-here-s-what-to-watch 2026-04-30 Longevity Trader en 2026-04-30T16:12:41Z This Regenerative Medicine Company Looks IPO-Ready. Here’s What to Watch